Maxwell Foundation

Maxwell Biosciences is a preclinical-stage biotechnology company focused on developing a new class of broad-spectrum anti-infective therapeutics called Claromers. These synthetic small molecules are peptidomimetics (specifically peptoids) designed to mimic the human innate immune system by targeting and destroying the structural integrity of viruses, bacteria, fungi, and biofilms. The company's platform aims to provide shelf-stable, non-toxic treatments that do not trigger antimicrobial resistance or harm the healthy microbiome. Maxwell is currently advancing its lead candidates toward FDA clinical trials, with a primary focus on infectious diseases, biodefense, and longevity-related health issues.